Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer - Contacts and Locations

Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer

This study has been completed.

Study NCT00073502. Last updated on February 17, 2006. Information provided by OSI Pharmaceuticals

Please refer to this study by its ClinicalTrials.gov identifier: NCT00073502

Locations


United States, Pennsylvania
	University of Pennsylvania Cancer Center
	Philadelphia, Pennsylvania, United States, 19104

United States, Texas
	MD Anderson Cancer Center
	Houston, Texas, United States, 77030

United States, Utah
	University of Utah, Huntsman Cancer Institute
	Salt Lake City, Utah, United States, 84112

Belgium
	Dept Internal Medicine Gastrointestinal Oncology Unit
	B-3000 Leuven, Belgium

United Kingdom
	NICCTU, East Podium, C-Floor
	Belfast, United Kingdom, BT9 7AB
	Beatson Oncology Centre
	Glasgow, United Kingdom, G11 6NT
	Department of Medical Oncology
	Manchester, United Kingdom, M20 4BX
	Cookridge Hospital
	Leeds, United Kingdom, LS16 6BB

United Kingdom, Avon
	Bristol Haematology & Oncology Centre
	Bristol, Avon, United Kingdom, BS2 8ED

United Kingdom, Oxfordshire
	ICRF Medical Oncology Unit
	Oxford, Oxfordshire, United Kingdom, OX3 7LJ

United Kingdom, West Midlands
	Deanesly Centre
	Wolverhampton, West Midlands, United Kingdom, WV10 0QP

Sponsors and Collaborators

OSI Pharmaceuticals